CCL5 and ovarian cancer: The conclusion is that CCL5 is a protumorigenic chemokine and a key target of miR-214, thus showing that microRNA perturbation in the stromal microenvironment can affect tumor growth by increasing the secretion of CCL5 by CAFs and suggesting that CCL5 is a possible therapeutic target in ovarian cancer.